Abstract
Background: The subcutaneous implantable cardioverter defibrillator (S-ICD) represents a major advancement in ICD technology in the last 10 years. During the experience with the 1nd generation of S-ICD, the IAS rate was 4,5% to 25% and with 2nd generation and 3nd generation of S-ICD the IAS rate was 3.1% at one year. Indeed, in the hospital and out of hospital emergency situations in presence of IAS it is mandatory to suspend the shock therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Online Journal of Cardiology Research & Reports
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.